Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed and Refractory (R/R) LBCL

NCT06149169 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06149169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06149169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed and Refractory (R/R) LBCL
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
August 17, 2023
Completion date
March 31, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, lymphoma, non-hodgkin